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Abstract In pharmaco-epidemiology, the use of drugs is
the determinant of interest when studying exposure-out-
come associations. The increased availability of comput-
erized information about drug use on an individual basis
has greatly facilitated analyses of drug effects on a popu-
lation-based scale. It seems likely that many negative
ﬁndings in the early days of pharmaco-epidemiology can
be explained by non-differential misclassiﬁcation because
of too simple (yes/no) exposure measures. In this paper, the
authors discuss the importance of an adequate deﬁnition of
drug exposure in pharmaco-epidemiological research and
how this time-varying determinant can be analyzed in
cohort studies. To reduce the risk of non-differential mis-
classiﬁcation, a precise deﬁnition of exposure is mandatory
and it is important to distinguish the complete follow-up
period of a population into mutually exclusive episodes
of non-use, past use and current use for each individual.
By analyzing exposure to drugs as a time-dependent vari-
able in a Cox regression model, cohort studies with com-
plete coverage of all ﬁlled prescriptions can provide us
with valid and precise risk estimates of drug-outcome
associations. However, such estimates may be biased in the
presence of time-dependent confounders which are them-
selves affected by prior exposure.
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Introduction
In pharmaco-epidemiology, the use of drugs is the determi-
nant of interest when studying exposure-outcome associa-
tions.Theincreasedavailabilityofcomputerizedinformation
about drug use on an individual basis has greatly facilitated
analyses of drug effects on a population-based scale. This
stimulated the development of pharmaco-epidemiology as a
branch within epidemiology as can be seen on epidemiolog-
ical congresses [1].
In the last decades of the preceding century, many
pharmaco-epidemiologic studies employed a case–control
design. Case–control studies of the association between
diethylstilboestrol against habitual abortion and vaginal
carcinoma in female offspring [2], and of salicylate-
attributed Reye syndrome [3] have clearly shown the
beneﬁts of this design thanks to their valid and relevant
results despite small numbers of cases in both studies.
However, in hindsight this design may also have risen
spurious associations such as that between use of reserpine
and breast cancer [4].
Because information about drug use in these early
studies had to be obtained from interview, they suffered
from two important potential limitations. First, the suspi-
cion that patients with severe diseases would tend to have a
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DOI 10.1007/s10654-010-9451-7better recall than non-diseased controls. This type of
information bias (so-called ‘recall bias’) was suspected to
be partly responsible for the association between X-ray
exposure during pregnancy, and the subsequent occurrence
of congenital malformations in off-spring [5]. In a sub-
sequent similar study with hospital records, the signiﬁcant
risk increase of 90% found earlier was brought back to
40%, albeit still statistically signiﬁcant [6]. Unfortunately,
even hospital records may be incomplete when information
of drug use is retrospectively gathered [7]. Second, whereas
recall bias leads to differential (i.e., non-random) mis-
classiﬁcation of exposure, also non-differential (i.e., ran-
dom) misclassiﬁcation may jeopardize the validity of drug-
effect estimates as can be seen in Fig. 1. The argument
which is often brought forward that such misclassiﬁcation
is less serious because it leads to a more conservative
estimate, is questionable as also underestimations are non-
valid and therefore unwanted. It seems likely that many
negative ﬁndings in the early days of pharmaco-epidemi-
ology can be explained by non-differential misclassiﬁ-
cation because of too simple (yes/no) exposure measures.
But even with extensive scrutiny of drug history during
interview, long-term exposure such as might be relevant to
development of end-stage renal failure [8] will inevitably
lead to both differential and non-differential exposure
misclassiﬁcation. It would not be fair to blame researchers
for this, as laborious investigation of serious diseases
should be praised and because most of them do not ignore
the limitations of their data.
In this paper, we discuss the importance of an adequate
deﬁnition of drug exposure in pharmaco-epidemiological
research and how this time-varying determinant can be
analyzed in cohort studies.
Drug assessment in populations
The two types of above-mentioned exposure misclassiﬁ-
cation can be effectively circumvented when drug use in
populations is prospectively gathered, i.e., before onset of
the event of interest and consequently unbiased. Prospec-
tive data collection prevents the occurrence of ‘recall bias’
or other types of differential exposure information bias.
Non-differential misclassiﬁcation, however, can still occur
if the exposure deﬁnition is imprecise or if drug use falls
outside the biologically plausible risk window, as can be
seen in Fig. 2. Although we know that prolonged use of
high doses of estrogens is a strong risk factor for liver
adenoma [9], for instance, it is clear that in a woman who
started using the drug 1 month before diagnosis, liver
adenoma can not be caused by the estrogen. Apparently,
exposure status is not merely a matter of using/non-using a
drug before the event occurs but also of timing. In real life
situations, the effect of exposure will depend on dose,
duration of use, timing in relationship to the event, con-
current medication, and adherence to therapy.
Of course, the fundamental question is: ‘‘what is expo-
sure ?’’. In an ideal situation, it tells us what the drug
concentration is at the receptor site which is responsible for
the biological effect. Obviously, such a situation can be
achieved at best in small groups of diseased or volunteers
and even there, it is a rather theoretical option and is
approached nearest with the assessment of drugs and their
metabolites in blood or plasma. As blood levels tell us little
about, for instance, the concentration of psychotropic drugs
in brain tissue, the contribution to large-scale population-
based pharmaco-epidemiology is modest although it will
add to interpreting the study results. Instead, large studies
rely on three types of health care data which are currently
becoming more and more readily available: drug exposure
information from health insurance companies or sick funds
Fig. 1 Assume a prospective cohort study with 10% non-differential
misclassiﬁcation of exposure. Without misclassiﬁcation, the true
relative risk would be calculated as [30/100]/[10/100] = 3.0 in those
treated with drug A in comparison to those on drug B. However,
because in diseased as well as non-diseased 10% of individuals
switches from A ? B and vice versa, the number of exposed changes
for each cell, i.e. cell a (30 - 3?1 = 28); cell b (70 - 7?9 = 72);
cell c (10 - 1?3 = 12); cell d (90 - 9?7 = 88). Consequently, we
calculate the relative risk as [28/100]/[12/100] = 2.3
Fig. 2 Assumeaprospectivecohortstudyontheriskofcancerinduction
after long-term exposure to a drug A. To reduce the effect of non-
differential misclassiﬁcation as much as possible, cumulative exposure
should only becalculatedduringthe inductionperiod(exposurewindow
2). If use during the latent period is included (exposure window 1), the
measured relative risk (RR) will be diluted from RR = 5 towards
RR = 2. This will be brought down even further to a RR = 1i f
cumulative exposure is only measured during the latent and disease
period (exposure window 3)
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123[10]; from general practitioners [11], and from pharmacies.
Data from general practitioners are of great value because
they consist of both drug prescriptions and information on
disease, and can not only show changes in prescribing [11]
but can also be pooled in large-scale collaborative research
[12] to study rare events. However, a limitation is that spe-
cialist prescriptions are incompletely registered in general
practice databases,and thatnotalloftheir ownprescriptions
are ﬁlled at pharmacies. As for health insurance companies,
not all of them register the daily dose of the patient. Conse-
quently, drug ﬁlling data from pharmacies come closest to
true exposure of prescription-only drugs. This holds espe-
cially in those who use chronic medication. People who
come back at regular intervals for reﬁlls of a drug, usually
have a high compliance to therapy. Dividing the number of
ﬁlled tablets or capsules by the daily prescribed number
makes it possible to calculate when a patients is expected to
comeforthenextvialofmedicines.Inthisway,adherenceto
therapycanbeassessedreliably.Allmentioneddatasources,
however, miss over-the-counter (OTC) drugs.
Converting ﬁlled prescriptions into exposure variables
For the analysis of drug-event associations, the dose, the
duration, and timing of use are highly important. Unfor-
tunately, individual medication histories may contain a
plethora of different drugs, doses, switching between
drugs, and types of administration. Most western countries
have some 10,000 different marketed drug products and it
is an administrative and pharmacological challenge to
convert this information into an analyzable dataset. Sup-
pose, for instance, that one would be interested to study the
association between long-term use of anti-inﬂammatory
drugs (NSAIDs) and cancer. Then, use of several different
pharmaceutical products over the years by one person has
to be brought back to the numbers of days of use of each
pharmacological entity, and to a standardized dose to
facilitate comparison between products. For instance, the
recommended daily dose for treatment of arthritic pain is
100 mg for diclofenac and 500 mg for naproxen. Taking
the average dose without standardization would be mean-
ingless. A well-known scheme for dose standardization is
the ATC-DDD scheme of the World Health Organisation
(http://www.whocc.no).
Drug-event analyses
Epidemiologists usually underline the importance of
awareness of potential confounding in study designs to
prevent non-validity [13]. For obvious reasons, appropriate
epidemiologic methods are a prerequisite for valid study
results. This includes the validation of exposure measure-
ment tools [14]. An adequate assessment of the role of
drug exposure requires knowledge of the biologically rel-
evant period during which the drug must be used to induce
or modify the event of interest, and of the pharmacokinetic
and pharmacodynamic properties of the drug. If we are
interested in the question whether a drug may cause an
event, we should only assess the exposure status during the
induction period as any assessment outside this period will
introduce non-differential misclassiﬁcation of exposure
(Fig. 2). On the other hand, if we investigate whether a
drug is not a cause but modiﬁes the disease process, we
will only assess the exposure status during the latent and/or
disease period. The pharmacodynamic effects of the drug
should be compatible with causation, although this may
not always be clear. The pharmacokinetic properties of a
drug are very important for assessing the duration of
exposure. For instance, a drug against cystitis such as
nitrofurantoin is excreted completely within hours while
the notorious carcinogenic diagnostic agent thorium diox-
ide which was used between the 30 and 50 s of the 20th
century has a biological half-life of 400 years and a
physical half-life of 5,000 years. Drugs such as the anti-
arrhythmic agent amiodaron and the anxiolytic diazepam
have prolonged carry-over effects because of their long
half-life. Apparently, the exposure period is not merely the
time during which the drug was actually taken but may
have to be extended with a carry-over period of 1–2
half-lives.
Analysis of drug exposure as a time-varying
determinant in prospective population-based cohort
studies
As mentioned above, the prospective gathering of drug use
facilitates unbiased risk estimates provided exposure is
precisely deﬁned by reference to a well-deﬁned event
with a clearly recognizable onset. Thanks to prospectively
gathered and complete medication histories, exposure
status can be assessed on every day of the follow-up. This
is a great advantage over population-based studies where
drug use is assessed on the basis of interview during
repeated rounds of cross-sectional measuring. Although the
analyses in this paper pertain to cohort studies, this
includes nested case–control studies where the prospective
exposure data come from the cohort but there are efﬁ-
ciency reasons to perform a case–control analysis. This
may occur, for instance, when tissue samples have to be
taken or when additional data gathering from medical
records makes it unfeasible to perform this in the whole
study cohort.
Analysis of individual drug use 247
123Unlike constant features such as sex and certain genetic
traits, drug use is essentially a time-varying determinant. In
a traditional Cox regression model [15], the hazard func-
tion in the total population at time point t is deﬁned as:
k t ðÞ¼k0 t ðÞ exp bx ðÞ ð 1Þ
inwhichk(t)representstheeventrateattimetconditionalon
being still event free before time t. In this model the event
rate is assumed to be equal to a baseline risk k0(t), which is
thesameforeverybodyinthepopulation,i.e.,independentof
the determinants. This baseline risk is multiplied by a term
exp(bx), dependent on the determinants x, which are
different between individuals. The parameters b quantify
the effect ofthe determinants on the event rate. They have to
be estimated from the data, together with the baseline risk
k0(t).Therearedifferentchoicespossibleforthetimescalet,
forinstance,t = age(whenageisstronglyandexponentially
associated with event occurrence), t = time since entry in
the cohort, or t = calendar time. In the simplest case, x
represents only one determinant x1, for instance sex, with
x1 = 1 (males) and x1 = 0 (females). Then k(t) gives the
hazard function for developing the event at time point t in
males or females. For females, the hazard is k0(t) and for
malesthehazardisk0(t)multipliedbyexp(b1).Inthismodel,
the determinants x are not necessarily constant during
follow-up, but may vary in time, such as drug use. In a study
sample, the unknown hazards are then estimated from the
data as:
ht ðÞ¼h0 t ðÞ exp b1x1 ðÞ ð 2Þ
Suppose that we performed a study in which m
individuals developed the event of interest during follow-
up. The follow-up times at which the events (the ‘‘cases’’)
occurred are denoted with t1,…, tm. (for simplicity, we
assume that events do not coincide). In a Cox proportional
hazards regression analysis with drug exposure as a time-
varying determinant [16], the exposure status x1[tj] on the
index day tj of the case number j, is compared to the
exposure status of all other cohort members on the same
day of the follow-up. In this way, j = 1,…, m strata are
formed of one case each and the other cohort members who
were still in the follow-up and event free at time tj as
controls. In an earlier analysis in The Rotterdam Study
[17], for instance, it was investigated whether thiazide
diuretics protect against hip fracture, thanks to their
calcium-retaining effect [18]. An analytical matrix would
look like the ones given in Table 1a and b. On the index
date tj, all cohort members have a history of thiazide use up
to that time. In its simplest form, we can characterize this
history as use on the index date as 1 (‘yes’) or 0 (‘no’) like
in Table 1a. If i denotes the number of an arbitrary cohort
member that is under follow-up at the index date tj, the
model states for this individual i
ht i ðÞ ¼ h0 tj
  
  exp b1x1i tj
     
ð3Þ
in which the time-varying determinant x1i[tj] has the
numerical value ‘1’ (exposed) or ‘0’ (unexposed) depend-
ingonwhethercohortmemberiisexposedornon-exposedat
timepointtj.Foreacheventtimetj,thereisasetRj(the‘‘risk
set’’) containing all individuals who were under observation
at tj. So, Rj contains case number j and its corresponding
controls.Giventheeventattj,theconditionalprobabilitythat
out of all cohort members in Rj the cohort member with
number j (the one who was observed to develop the event)
will develop the event is:
h0 tj
  
  exp b1x1j tj
     
=
X
ifromRj
h0 tj
  
  exp b1x1i tj
        
ð4Þ
Notice that the baseline hazard rate h0(tj) is present in
numerator and denominator and cancels out. Therefore, the
conditional likelihood function of all the data, deﬁned as
the product of the probabilities as given in (4) over all
event times tj, is equal to:
L b ðÞ ¼P
m
j¼1
fexp b1x1j tj
     
=
X
ifromRj
exp b1x1i tj
     
g
However, this straightforward but simple analysis with
only the status exposed/unexposed would mean that we use
onlyaverylimitedpartoftheinformationthatiscontainedin
the thiazide use history and thereby introduce non-
differential misclassiﬁcation. As can be seen in Table 1a,
knowingthe numbers of daysof continuous use on the index
date of each cohort member facilitates calculation of more
validriskestimatesasitisunlikelythatonly1 dayofthiazide
use would already be protective while the model would
consider even those people as exposed who started thiazides
1 day before the index date. There are pharmacological
reasonstoassumethataprotectiveeffectonhipfracturemay
become visible only after at least 6 weeks of calcium
retentionbythiazidetreatmentandreachesamaximumafter
*1 year. Hence, more information, and consequently less
non-differential misclassiﬁcation, is obtained with the
introduction of extra determinants x2, and x3, where the
cumulative continuous exposure to thiazides at the index
date is categorized as: x1 = 1 through 42 days; x2 = 42
through 365 days; x3[365 days.
ht ðÞ¼h0 t ðÞ exp b1x1 t ½ þb2x2 t ½ þb3x3 t ½  ðÞ ð 5Þ
In this way, the risk for these two exposure categories is
expressed in comparison to non-use and yields a more valid
representation of the drug-event association than in (3) or
when thiazide exposure in days would be introduced as a
continuous exposure determinant.
Even more information, and therefore less non-differ-
ential misclassiﬁcation, may follow from the introduction
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over period should be taken into account. For instance, if
thiazide use for more than 1 year results in a higher calci-
ﬁcation of the hip, it will take a certain time period before
discontinuation of thiazides results in returning to the
situation before starting treatment. This can be done by
introducing determinants for past exposure, deﬁned as the
number of days since last intake of thiazides (Table 1b). In
the previously mentioned study, additional categorical
determinants were created as extra determinants x4, x5, and
Table 1 Apart from unique patient number, sex and age in years, the
columns respectively represent: case status (1 = ‘yes’; 0 = ‘no’);
stratum; follow-up in days; cumulative number of days of current use;
number of days since last intake in past users; deﬁned daily dose
(DDD) [for hydrochlorothiazide: 25 mg and for chlorothiazide:
500 mg]; and total numbers of days of use since study entry
Patient Sex Age Case Stratum Follow-up Current use
(a)
4417001 V 82 1 1 961 0
6593001 V 88 0 1 961 0
1101001 V 93 0 1 961 0
3000001 M 81 0 1 961 0
5135001 V 86 0 1 961 0
1720215 V 88 0 1 961 1
6367517 V 86 0 1 961 0
2191001 V 74 0 1 961 1
1033001 V 87 0 1 961 0
7112001 F 88 1 2 1,253 1
1376809 M 94 0 2 1,253 0
Patient Sex Age Case Stratum Follow-up Current use Past use
(b)
4417001 V 82 1 1 961 0 0
6593001 V 88 0 1 961 0 0
1101001 V 93 0 1 961 0 90
3000001 M 81 0 1 961 0 0
5135001 V 86 0 1 961 0 0
1720215 V 88 0 1 961 154 0
6367517 V 86 0 1 961 0 0
2191001 V 74 0 1 961 83 0
1033001 V 87 0 1 961 0 0
7112001 F 88 1 2 1,253 34 0
1376809 M 94 0 2 1,253 0 0
Patient Sex Age Case Stratum Follow-up Current use Past use DDD Total use
(c)
4417001 V 82 1 1 1,061 0 0 – 0
6593001 V 88 0 1 1,061 0 0 – 0
1101001 V 93 0 1 1,061 0 90 – 387
3000001 M 81 0 1 1,061 0 0 – 0
5135001 V 86 0 1 1,061 0 0 – 0
1720215 V 88 0 1 1,061 154 0 1.2 234
6367517 V 86 0 1 1,061 0 0 – 0
2191001 V 74 0 1 1,061 83 0 0.9 83
1033001 V 87 0 1 1,061 0 0 – 0
7112001 F 88 1 2 1,253 34 0 1.7 731
1376809 M 94 0 2 1,253 0 0 – 0
Note that the total use is mostly higher than current use because patients may have used thiazides intermittently
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counting back from the index date, was categorized as:
x4 = 1 through 60 days; x5 = 61 through 365 days; and
x6[365 days.
For obvious reasons, the determinants x1 through x6
should be introduced in one model. After all, it is important
that the complete follow-up time of each study member is
expressed in mutually exclusive episodes of non-use, past
use, and current use to decrease the degree of non-differ-
ential misclassiﬁcation as much as possible. Then, the full
model is:
ht ðÞ¼h0 t ðÞ expðb1x1 t ½ þb2x2 t ½ þb3x3 t ½ þb4x4 t ½ 
þ b5x5 t ½ þb6x6 t ½  Þ
ð6Þ
This model can be extended with the inclusion of other
non-time-varying determinants such as gender and baseline
age xa, xb, …, xj, …, xz, provided usual precautions against
overﬁtting of the model are taken into account. Adjusting
for dosage may be performed by including it as a
continuous determinant in mg/day or categorized, for
instance by splitting current use as: current use with [1
deﬁned daily dose (DDD); current use with B1 DDD.
The analytical matrix in Table 1c facilitates different
type of analyses. For instance, would we be interested to
ﬁnd out whether cumulative use of nonsteroidal antiin-
ﬂammatory drugs (NSAID) are associated with an
increased risk of cancer, we might prefer to use the
determinant ‘total use’. However, if we would be interested
in induction, rather than promotion, we might subtract a
theoretical episode of 5 years from the index date of cancer
diagnosis and calculate total use in days until that date, or
in dose as cumulative DDDs. We would do this to avoid
non-differential misclassiﬁcation by restricting ourselves to
the induction period. Would we only be interested in pro-
motion, we would treat NSAID as an effect modiﬁer and
restrict our analysis to total use in the 5 years before cancer
diagnosis because we would expect that malignant cells
would already be present during that latent period.
Limitations
The method described above facilitates a clear insight into
the data structure but may have some practical limitations.
First, in patients who use drugs very irregularly, it may be
difﬁcult to calculate the cumulative period of continuous
current use at the index date as in such patients these
periods will usually be short and irregular. However, this
can often be circumvented by combining current and total
use. Second, because for every case the remainder of non-
censored cohort members serves as a reference, huge strata
may lead to substantial computational time to run analyses.
For instance, with 1000 cases in a cohort of 50,000 people,
each stratum would have slightly less than 50,000 obser-
vations at the index date of that stratum, leading to a data
ﬁle of *50,000,000 records. As there are techniques to
deal with such a problem, however, this may only be rel-
evant to the less well-equipped researcher.
A methodological limitation may arise when the model
is adjusted for a time-dependent co-variable which is a risk
factor for the event of interest and may be inﬂuenced by the
drug exposure [19]. Standard methods for estimating the
effect of a time-varying exposure on survival may be
biased in the presence of time-dependent confounders
which are themselves affected by prior exposure. This
problem can be overcome by inverse probability weighted
estimation of Marginal Structural Cox Models (Cox MSM)
or G-estimation of Structural Nested Cumulative Failure
Time Models (SNCFTM). For this situation, the reader is
referred to recent literature about such a scenario [20].
Conclusion
In pharmaco-epidemiology, the use of drugs is the deter-
minant of interest when studying exposure-effect associa-
tions. It seems likely that many negative ﬁndings in the
early days of pharmaco-epidemiology can be explained by
non-differential misclassiﬁcation because of too simple
(yes/no) exposure measures. To reduce the risk of non-
differential misclassiﬁcation, a precise deﬁnition of expo-
sure is mandatory and it is important to distinguish the
complete follow-up period of a population into mutually
exclusive episodes of non-use, past use and current use for
each individual. By analyzing exposure to drugs as a time-
dependent variable in a Cox regression model, cohort
studies with complete coverage of all ﬁlled prescriptions
can provide us with valid and precise risk estimates of
drug-outcome associations. However, such estimates may
be biased in the presence of time-dependent confounders
which are themselves affected by prior exposure.
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